Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (35)

I-07

Clinical trial simulations of the anticancer agents- abiraterone and nilotinib

Wednesday 10:15-11:45

I-23Maria Matoses Osborne

Development of a PBPK model for the anticancer drug Vivia009 and its main metabolite administered as a new delivery system in the Rat

Wednesday 10:15-11:45

I-25Christophe Meille

Modified model of drug induced thrombocytopenia efficiently projects safe starting dose in human from preclinical data

Wednesday 10:15-11:45

I-45Zinnia Parra-Guillen

Tumour Growth Modelling In Immunotherapy

Wednesday 10:15-11:45

I-46

Modeling of the effect of G-CSF in limiting the neutropenic toxicity of carboplatin

Wednesday 10:15-11:45

I-58Sylvie Retout

Prediction of occurrence of thrombocytopenia to select Phase 1b dose and dosing regimen for a selective inhibitor of p53-MDM2 in patients with solid tumors

Wednesday 10:15-11:45

I-59Benjamin Ribba

A model for low-grade glioma tumor growth and response to chemotherapy and radiotherapy

Wednesday 10:15-11:45

I-66Hauke Ruehs

Integrated PK/PD model for oxaliplatin in different human matrices

Wednesday 10:15-11:45

II-05Maria Luisa Sardu

Biomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies

Wednesday 15:10-16:40

II-07Emilie Schindler

PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib

Wednesday 15:10-16:40

II-43Coen van Hasselt

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab

Wednesday 15:10-16:40

II-58Shelby Wilson

The Enhancement of Tumor Vaccine Efficacy by Immunotherapy

Wednesday 15:10-16:40

II-59Gudrun Wuerthwein

Population Pharmacokinetics of caspofungin in a phase II dose escalation study

Wednesday 15:10-16:40

II-60Wenyuan Xiong

Pharmacokinetic interspecies extrapolation of a fully human mAb from animal to human

Wednesday 15:10-16:40

II-63Jianping Zhang

Population Analysis of Tumor Growth Inhibition and Progression-Free Survival Following Lapatinib Treatment in Patients with Advanced/Metastatic Breast Cancer

Wednesday 15:10-16:40

III-03

Capecitabine: a pharmacokinetic model derived from its clinical use

Thursday 10:05-11:35

III-06

Mechanistic NSCLC vascular tumor model: insights to prognosis towards personalized medicine

Thursday 10:05-11:35

III-12

Model-based analysis of disease progression in pancreatic cancer based on registry data collected from the Surveillance, Epidemiology, and End Result (SEER) database

Thursday 10:05-11:35

III-14Brendan Bender

A multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer

Thursday 10:05-11:35

III-31Núria Buil Bruna

Modeling evaluation of different in vitro experimental designs to characterise antitumor drug effect

Thursday 10:05-11:35

III-35Quentin Chalret du Rieu

Semi-mechanistic thrombocytopenia model of a new histone deacetylase inhibitor (HDACi) in development, with a drug-induced apoptosis of megakaryocytes.

Thursday 10:05-11:35

III-43

Evaluation of Tumor-Size Response Metrics to Predict Survival and Progression Free Survival in First-Line Metastatic Colorectal Cancer

Thursday 10:05-11:35

III-46Damien Cronier

Population Pharmacokinetic Study of a New Humanized Anti-CD20 Monoclonal Antibody AME-133v (LY2469298) in Patients with Previously Treated Folicular Lymphoma.

Thursday 10:05-11:35

III-48Elyes Dahmane

The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial.

Thursday 10:05-11:35

III-68

A database of PK-PD parameters and information for the modelling of anti-cancer drug regimen and combinations

Thursday 10:05-11:35

IV-05Lena Friberg

Myelosuppression as a Biomarker of Tumor Response in Docetaxel Treated Metastatic Breast Cancer Patients

Thursday 15:00-16:30

IV-15Pascal Girard

Simultaneous Ocular Adverse Event and Treatment Discontinuation Model of Pimasertib

Thursday 15:00-16:30

IV-21Verena Gotta

Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions

Thursday 15:00-16:30

IV-26Ivelina Gueorguieva

Development Of Integrated Pharmacokinetic/Pharmacodynamic (PK/PD) Model For The Novel TGF- β Inhibitor LY2157299 Monohydrate: Preclinical To Phase II

Thursday 15:00-16:30

IV-28Emma Hansson

PKPD Modeling of Predictors for Side Effects and Overall Survival in Patients with Gastro Intestinal Stromal Tumor Treated with Sunitinib

Thursday 15:00-16:30

IV-31Tomi Hendrayana

Population pharmacokinetic (PK) model for fluorouracil (5-FU) accounting for irregularities in infusion rate

Thursday 15:00-16:30

IV-32Emilie Hénin

A latent-variable model for Sorafenib-induced Hand-Foot Syndrome (HFS) in non-selected patients to predict toxicity kinetics according to sorafenib administrations

Thursday 15:00-16:30

IV-49Amita Joshi

A physiologically-based pharmacokinetic (PBPK) approach to evaluate differences in pharmacokinetics between healthy subjects and cancer patients

Thursday 15:00-16:30

IV-51

Modeling Sunitinib and Biomarker Response as potential Predictors of Time to Progression in Patients with Metastatic Colorectal Cancer

Thursday 15:00-16:30

IV-63Steve Kuan

Population Pharmacokinetic (PK) Modelling of Bortezomib After Bolus Intravenous Injection in Cancer Patients

Thursday 15:00-16:30